AG真人官方

Trinity Capital Inc. (Nasdaq: TRIN) filed a Form 8-K disclosing that on June 26, 2025 it executed an Underwriting Agreement with Keefe, Bruyette & Woods, Inc. and Morgan Stanley & Co. LLC, acting for several underwriters, to issue and sell $125 million aggregate principal amount of 6.750% senior unsecured notes due 2030 (the 鈥淣otes鈥�).

The Notes are being offered under the company鈥檚 effective shelf registration statement on Form N-2 (File No. 333-275970) and related prospectus supplements dated June 26, 2025. Closing is scheduled for July 3, 2025.

The agreement contains customary representations, warranties, covenants, indemnification and contribution provisions. Exhibit 1.1 provides the full Underwriting Agreement; Exhibit 104 contains the Inline XBRL cover-page data.

No other material events were reported. The filing does not constitute an offer or solicitation where prohibited by law.

Michael Ellenbogen, Founder & Chief Innovation Officer and Director of Evolv Technologies Holdings, reported significant changes in beneficial ownership on June 23, 2025. The key transaction involved the transfer of investment control of 2,259,987 shares of Class A Common Stock previously held by E Ventures Trust to an independent investment advisor.

Following this transaction, Ellenbogen's holdings include:

• 2,083,961 shares held directly
• 151,135 shares held indirectly through Family Horizon Trust

The transfer of investment control means Ellenbogen no longer has beneficial ownership of the E Ventures Trust shares and will not include them in future Section 16 reports. This represents a significant change in his control over company shares while maintaining his executive and board positions.

Evolv Technologies Holdings (NASDAQ: EVLV) filed a Form 4 detailing routine equity movements by director Richard A. Shapiro. On June 19 2025 he acquired 12,515 Class A shares at $0 when a prior restricted stock unit (RSU) award vested. A day later, on June 20 2025, he received a new grant of 27,050 RSUs that will vest in full on the earlier of June 20 2026 or the day before the next annual meeting. Following these transactions Shapiro now holds 22,515 shares directly, plus indirect interests鈥�30,000 shares held by his spouse, 15,000 in a trust, and 7,600 in a spouse retirement plan鈥攆or a combined indirect total of 52,600 shares. No shares were sold, and the transactions represent standard non-employee director compensation rather than open-market purchases or sales.

Bank of Montreal (BMO) is offering Senior Medium-Term Notes, Series K 鈥� Contingent Risk Absolute Return Buffer Notes due January 4, 2027 that are linked to the S&P 500庐 Index. The notes give investors 1-to-1 upside exposure to any index appreciation, but gains are capped at a Maximum Return of 9.00% (US $1,090 per US $1,000 principal). The structure also provides a limited positive 鈥渂uffer鈥� if the index declines: should the Final Level fall below the Initial Level yet remain above the Buffer Level of 80 % of the Initial Level, holders receive a positive return equal to the absolute percentage decline, up to the Maximum Downside Redemption Amount of US $1,200 (20 % return) per note.

If the S&P 500庐 drops by more than 20 %, investors lose principal on a 1-for-1 basis beyond the buffer, exposing them to a potential maximum loss of 80 %. The notes pay no periodic interest, are unsecured and unsubordinated obligations of BMO, and are not listed on any exchange, which may materially limit liquidity. All payments depend on BMO鈥檚 creditworthiness; the notes carry the same credit risk as BMO鈥檚 other senior debt.

Key economic terms include:

• Upside Leverage Factor: 100 %
• Maximum Redemption Amount: US $1,090 per US $1,000
• Buffer Percentage: 20 %
• Pricing Date: June 27 2025 (expected)
• Maturity Date: January 4 2027 (鈮� 18 months tenor)
• Estimated initial value: US $974.10 (97.41 % of face); could be as low as US $925 on pricing date
• Price to public: 100 % of face; Agent鈥檚 commission: 1.80 %
• CUSIP: 06376ELT7; minimum denomination: US $1,000

The offering involves several material risks outlined in the 鈥淪elected Risk Considerations,鈥� notably (1) principal loss beyond the 20 % buffer, (2) limited upside, (3) credit risk of BMO, (4) lack of secondary-market liquidity, (5) conflicts of interest in BMO鈥檚 dual role as issuer and calculation agent, and (6) uncertain U.S. tax treatment (pre-paid derivative contract). Hedging, market factors and BMO鈥檚 funding rate are expected to lower secondary-market valuations relative to issue price.

These notes may appeal to investors who are moderately bullish or range-bound on the S&P 500庐 over the 18-month term and who are willing to cap upside in exchange for limited downside protection. They are not appropriate for investors requiring principal protection, periodic income or daily liquidity.

Evolv Technologies (NASDAQ:EVLV) filed a routine Form 4 disclosing an equity award to director Neil Glat. On June 20, 2025, Glat received 27,050 Restricted Stock Units (RSUs), each representing one share of Class A common stock. The RSUs carry no exercise price and will vest in full on the earlier of June 20, 2026 or the day immediately preceding the company鈥檚 next annual meeting. Following the grant, Glat beneficially owns 27,050 shares directly. No sales, dispositions, or other material transactions were reported.

Form 4 filing: On 06/20/2025 Evolv Technologies Holdings, Inc. (EVLV) reported that Director Kimberly H. Sheehy received 27,050 Restricted Stock Units (RSUs). Each RSU converts into one share of Class A common stock and carries no exercise price.

The RSUs vest in full on the earlier of 06/20/2026 or the day immediately preceding the company鈥檚 next annual meeting, promoting near-term board alignment. No shares were sold or disposed of, and the entire award is held directly by the reporting person. After the grant, Sheehy beneficially owns 27,050 derivative securities tied to EVLV shares.

This appears to be a routine director compensation grant. While it slightly increases potential share count, the dilution effect is minimal. Nonetheless, the award strengthens the director鈥檚 economic stake, which investors may view as a modestly positive governance signal.

Director Mark J. Sullivan of Evolv Technologies Holdings (EVLV) received a grant of 27,050 Restricted Stock Units (RSUs) on June 20, 2025. Each RSU represents the right to receive one share of Class A common stock.

Key terms of the RSU grant:

• The RSUs will fully vest on the earlier of June 20, 2026 or the day before the next annual meeting
• The RSUs were granted at no cost ($0)
• The securities are held in direct ownership
• The RSUs have no expiration date

This Form 4 filing was submitted by Rachel Roy as attorney-in-fact for Mark Sullivan on June 24, 2025, within the required reporting window for insider transactions.

Evolv Technologies Holdings, Inc. (EVLV) 鈥� Form 4 Insider Transaction

Director Bilal Zuberi reported the receipt of 27,050 Restricted Stock Units (RSUs) on 20 June 2025. Each RSU converts into one share of EVLV Class A common stock upon vesting. The award will vest in full on the earlier of 20 June 2026 or the day immediately preceding the company鈥檚 next annual shareholder meeting. No cash was paid for the RSUs (exercise price = $0), and there is no expiration date.

Following the grant, Zuberi beneficially owns 27,050 derivative securities; no additional non-derivative share holdings were disclosed in this filing. The filing reflects standard equity compensation for board members and does not indicate any share sales or purchases in the open market.

Given EVLV鈥檚 public float, the share count involved is immaterial from a dilution standpoint, but the award reinforces director/shareholder alignment without immediate cash outflow by the company.

Evolv Technologies Holdings (EVLV) reported a Form 4 filing disclosing an insider transaction by Director David Mounts Gonzales on June 20, 2025. The director was granted 27,050 Restricted Stock Units (RSUs) as part of the company's equity compensation plan.

Key details of the RSU grant:

• Each RSU represents a right to receive one share of Class A common stock
• The RSUs were granted at $0 cost to the director
• Vesting will occur in full at the earlier of June 20, 2026 or the day before the next annual meeting
• The RSUs have no expiration date

This transaction appears to be part of standard director compensation arrangements. The filing was signed by Rachel Roy as attorney-in-fact for David Mounts Gonzales on June 24, 2025.